If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

14 Sep 2016 17:27

RNS Number : 8758J
GW Pharmaceuticals PLC
14 September 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

c.

Price(s) and volume(s)

 

Price(s)

 28.15p

Volume(s)

198,288

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

13 September 2016

f.

Place of the transaction

 London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: 36197T1034

b.

Nature of the transaction

Conversion of 198,288 Ordinary shares into American Depositary Shares (12 to 1 conversion ratio) to create 16,524 ADSs

 

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

16,524

 

ADS's issued upon conversion of 198,288 Ordinary shares

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

13 September 2016

f.

Place of the transaction

Outside a trading venue

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

 

c.

Price(s) and volume(s)

 

Price(s)

 $98.75

Volume(s)

16,524

 

ADS's sold

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

13 September 2016

f.

Place of the transaction

Nasdaq, New York

 

 

Explanatory note: On 13 September 2016 Dr Stephen Wright exercised options to acquire 198,288 0.1 pence Ordinary shares for an average exercise price of 28.15 pence per share. These were immediately converted into 16,524 American Depositary Shares and sold via Nasdaq for an average price of $98.75 per ADS. The sale represents less than 0.1% of shares in issue. This sale of shares by Dr Stephen Wright is in accordance with the disclosures contained within the prospectus dated 14 July 2016 whereby the sale of up to 200,000 Ordinary shares by Dr Wright was agreed by the underwriters to be specifically excluded from the lock-up arrangements entered into by the Directors of the Company.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFFRARISLIR
Date   Source Headline
15th Dec 20113:19 pmRNSAnnual Report & Accounts & Notice of AGM
12th Dec 20117:00 amRNSGW Director Wins Wellcome Medal
5th Dec 20113:16 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSFinal Results
22nd Nov 20117:00 amRNSAPPLICATION TO EXPAND SATIVEX® EUROPEAN APPROVALS
17th Nov 20117:00 amRNSEUROPEAN PATENT GRANTED FOR SATIVEX® FORMULATION
24th Oct 201111:00 amRNSSativex Phase III data presented at ECTRIMS
12th Oct 201111:05 amRNSDirector/PDMR Shareholding
5th Oct 20112:51 pmRNSHolding(s) in Company
5th Oct 20112:50 pmRNSHolding(s) in Company
3rd Oct 201112:30 pmRNSDirector/PDMR Shareholding
14th Sep 20117:00 amRNSDirector/PDMR Shareholding
31st Aug 201110:02 amRNSHolding(s) in Company
31st Aug 201110:01 amRNSHolding(s) in Company
17th Aug 20113:29 pmRNSBlocklisting Interim Review
18th Jul 20117:00 amRNSSativex Regulatory Approval
11th Jul 20114:40 pmRNSSecond Price Monitoring Extn
11th Jul 20114:35 pmRNSPrice Monitoring Extension
4th Jul 20117:00 amRNSSativex® launched in Germany
30th Jun 20114:53 pmRNSDirector/PDMR Shareholding
30th Jun 20117:00 amRNSSecond Phase III Pain Trial Commences
8th Jun 20115:01 pmRNSDirector/PDMR Shareholding
8th Jun 20113:01 pmRNSDirector/PDMR Shareholding
8th Jun 20117:00 amRNSRegulatory Approval
3rd Jun 201111:00 amRNSDirector/PDMR Shareholding
26th May 20117:00 amRNSRegulatory Approval
18th May 20111:14 pmRNSBlocklisting Application
17th May 20117:00 amRNSHalf Yearly Report
28th Apr 20117:00 amRNSNotice of Results - Amendment
27th Apr 20115:59 pmRNSNotice of Results
20th Apr 20117:00 amRNSUS Patent Granted for Sativex in Cancer Pain
15th Apr 20117:00 amRNSRegulatory Approval
11th Apr 20117:00 amRNSExclusive Licence Agreement Signed with Novartis
25th Mar 20114:40 pmRNSSecond Price Monitoring Extn
25th Mar 20114:35 pmRNSPrice Monitoring Extension
25th Mar 20114:15 pmRNSDirector/PDMR Shareholding
22nd Mar 20117:00 amRNSSativex Mutual Recognition Procedure Closes
15th Mar 20114:40 pmRNSSecond Price Monitoring Extn
15th Mar 20114:35 pmRNSPrice Monitoring Extension
14th Mar 20117:00 amRNSSativex launched in Spain
2nd Mar 20117:00 amRNSPositive Sativex Study in MS Spasticity Published
22nd Feb 20118:23 amRNSHolding(s) in Company
17th Feb 20115:47 pmRNSBlocklisting Application
17th Feb 20115:46 pmRNSBlocklisting Interim Review
17th Feb 20115:42 pmRNSIssue of Equity
17th Feb 20117:00 amRNSSativex granted reimbursement in Spain
9th Feb 201110:25 amRNSDirector/PDMR Shareholding
19th Jan 20115:05 pmRNSAGM Resolutions passed
17th Jan 20117:00 amRNSReceipt of Milestone Payment
20th Dec 20109:29 amRNSAdviser - Change of Name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.